Pacer Advisors’s Cytek Biosciences CTKB Stock Holding History

Pacer Advisors’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-30,155	Closed	-$196K	–	3678
2024 Q4	$196K	Buy	+30,155	New	+$180K	﹤0.01%	1969

Other funds holding CTKB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return

TCM

Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Pacer Advisors's CTKB Position: Q1 2025 in Review

Pacer Advisors sold out of Cytek Biosciences (CTKB) in Q1 2025, closing a stake of 30,155 shares — an estimated $196K sold.

Pacer Advisors first reported a position in CTKB in Q4 2024 and held it in 1 quarter. The position peaked at $196K in Q4 2024. 160 funds tracked by Wall St. Rank hold CTKB as of Q1 2025.

Pacer Advisors reported no remaining Cytek Biosciences position as of Q1 2025 after selling out during the quarter.
Pacer Advisors sold 30,155 Cytek Biosciences shares in Q1 2025, an estimated $196K.
Pacer Advisors first reported a position in Cytek Biosciences in Q4 2024 and held it in 1 quarter.
Pacer Advisors's Cytek Biosciences position peaked at $196K in Q4 2024.
160 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2025.

Based on Pacer Advisors's 13F filing for Q1 2025, filed 6 May 2025.